Opioid Policy At US FDA: Gottlieb Seeks More Activist Role To Combat Abuse

‘Dramatic action’ needed to curb opioid epidemic, commissioner-nominee says, including potentially a cross-center approach to evaluating drugs and devices for pain, and new nomenclature for formulations currently labeled as abuse deterrent.

US FDA Commissioner-nominee Scott Gottlieb pledged to set the agency on a more activist course and “push the boundaries of the policy framework” to curb prescription opioid abuse if confirmed to the leadership post.

Enhanced scrutiny of the abuse liability for new drugs, new nomenclature around abuse-deterrent opioid formulations, and a more aggressive agency...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA

More from Agency Leadership